Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases

Background and aimsDespite proven clinical efficacy of vedolizumab (VDZ) for inducing and maintaining remission in patients with Crohn’s disease (CD) and ulcerative colitis (UC), subgroups of patients have no therapeutic benefit from anti-α4β7 integrin therapy with VDZ. Within this study, we aimed t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Timo Rath, Ulrike Billmeier, Fulvia Ferrazzi, Michael Vieth, Arif Ekici, Markus F. Neurath, Raja Atreya
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2018-07-01
Colecção:Frontiers in Immunology
Assuntos:
inflammatory bowel diseases
ulcerative colitis
Crohn’s disease
vedolizumab
RNA sequencing
integrin
Acesso em linha:https://www.frontiersin.org/article/10.3389/fimmu.2018.01700/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados